Healio

Increasing tocilizumab dose interval reduces chance of maintaining remission in RA

Please provide your email address to receive an email when new articles are posted on . Increasing the dose interval of subcutaneous tocilizumab is associated with a lower chance of maintaining ...
ascopubs.org

Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment ...

Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab. This is an ASCO Meeting Abstract from the 2019 ASCO Annual ...
MedPage Today

Increasing Tysabri Dosing Interval May Cut PML Risk

WASHINGTON -- Freedom from relapse was maintained in multiple sclerosis patients on natalizumab (Tysabri) who received the infusion drug less frequently than the recommended 4-week interval, with ...
Healio

Incidence rates increase, time intervals decrease with every subsequent cSCC

Please provide your email address to receive an email when new articles are posted on . Incidence rates for second through sixth cSCCs increased (28% to 67%), while time intervals decreased (1.4 to ...